Purpose: To define the physical parameters needed to characterize a particle beam in order to allow intercomparison of different experiments performed using different ions at the same facility and using the same ion at different facilities. Methods: At the request of the National Cancer Institute (NCI), a special panel was convened to review the current status of the field and to provide suggested metrics for reporting the physical parameters of particle beams to be used for biological research. A set of physical parameters and measurements that should be performed by facilities and understood and reported by researchers supported by NCI to perform pre-clinical radiobiology and medical physics of heavy ions were generated. Results: Standard measures such as radiation delivery technique, beam modifiers used, nominal energy, field size, physical dose and dose rate should all be reported. However, more advanced physical measurements, including detailed characterization of beam quality by microdosimetric spectrum and fragmentation spectra, should also be established and reported. Details regarding how such data should be incorporated into Monte Carlo simulations and the proper reporting of simulation details are also discussed. Conclusions: In order to allow for a clear relation of physical parameters to biological effects, facilities and researchers should establish and report detailed physical characteristics of the irradiation beams utilized including both standard and advanced measures. Biological researchers are encouraged to actively engage facility staff and physicists in the design and conduct of experiments. Modeling individual experimental setups will allow for the reporting of the uncertainties in the measurement or calculation of physical parameters which should be routinely reported.
INTRODUCTION
There is growing interest in the use of particle beams for cancer therapy with the goals of reducing side effects and potentially improving tumor control. Clinically, particle therapy includes the use of lighter ions such as protons as well as heavier ions, particularly carbon. 1 Despite the increasing clinical utilization of particle therapy, substantial uncertainties remain regarding the relation of physical factors to biological effects. Such uncertainties may hinder the understanding and improvement of the clinical effectiveness of particle therapy.
In photon therapy, dose is the primary parameter responsible for biological effects. High dosimetric accuracy has been repeatedly shown as a critical component of achieving expected outcomes, 2 even when radiation dose is not the study question. For example, inaccuracies in the standard of care radiation dose were found to have a more substantial impact on patient survival than even the theorized impact of a novel pharmaceutical agent being tested in a phase III clinical trial. 3 The issues of dosimetric accuracy and intercomparability between beams and studies become even more complicated in particle beam therapy because the effectiveness of these ions cannot be solely judged by physical dose. Particularly with heavy ion therapy, the primary and secondary particle spectral characteristics and patterns of energy deposition vary substantially along the beam path and impact biologic effects. Heavy ions have higher linear energy transfer (LET) values, which vary as a function of location within a given treatment field, resulting in enhanced but locally varying biological effectiveness. 4 Moreover, unlike photon therapy, clinical outcome data for patients treated with particle therapy are relatively sparse. 5 Relative biological effectiveness (RBE) in particle therapy is defined as the ratio of the absorbed dose of megavoltage x rays (or other reference radiation) to the absorbed dose of particle radiation producing the same biological effect. The use of photon-equivalent Gy (CGE or GyE, now officially indicated as Gy (RBE) 6 ) was adopted for clinical dose prescription from the outset of particle therapy. With both clinical and animal data lacking, and the nonexistence of human clinical trials to study RBE, prediction of RBE, and therefore Gy (RBE), relies almost exclusively on in vitro data.
In the case of proton radiotherapy, a constant RBE of 1.1 is commonly applied in clinical settings. 7 Although it is well known that RBE is not a constant value along the proton spread-out-Bragg-peak (SOBP), [8] [9] [10] [11] the use of a constant RBE has been considered as an acceptable approximation in most clinical applications. The relevance of a variable RBE in proton therapy is now widely discussed, and specific strategies to assess the potential of proton RBE in treatment planning are under study.
Using a variable RBE along the SOBP is a standard for heavy ion therapy. 1, 12 It is worth noting that during the earlier application of Carbon ion therapy at IMP Carbon Ion Center in Lanzhou (China) a constant RBE was used. For clinical treatments with heavy ions, such as carbon, models such as the microdosimetric kinetic model (MKM), Local Effect Model (LEM) or mixed beam model have been developed to generate treatment plans for clinical use. These models predict RBE-weighted dose and were primarily developed and benchmarked based on in vitro survival data. However, existing models vary greatly in their predictions of biological effect and are affected by dramatic uncertainties. This may impact clinical outcomes, and the use of different models greatly complicates the interpretation of clinical results between various centers.
Given the reliance of existing RBE models on in vitro data, a clear understanding of the relation of physical parameters to biological effect could allow for the refinement of models to improve predictive power. The clinical implementation of refined models could both standardize clinical treatments and improve outcomes for patients treated with particle therapy. However, the data necessary to develop such models may only be generated through the conduct of wellcharacterized experiments in which close consideration is given to minimizing not only the biological but also the physical uncertainties.
Especially for heavy ions, the quality of individual beams (e.g., beams at pure research facilities vs. those used clinically) may differ and impact the biological effectiveness and interpretation of results. Because the accuracy of biological response data depends on the accuracy of physical parameters, this represents a serious challenge for researchers seeking to obtain high quality in vivo and in vitro data. Physical parameters which may vary between beams may include simple factors such as dose rate and uniformity as well as more complicated factors such as spectra of fragmentation products, LET, lineal energy etc. Further complicating the interpretation of data, in order to analyze the results of an experiment, the beam must be characterized at the location of the biological sample. Such a detailed characterization may often rely on Monte Carlo (MC) simulations of the setup, but such simulations are sensitive to uncertainties in the input parameters.
In order to facilitate high quality biological research, the National Cancer Institute (NCI) convened a special panel with the following goal: to define the physical parameters needed to characterize a particle beam in order to allow intercomparison of different experiments performed using different ions at the same facility and using the same ion at different facilities.
This report is intended to inform facilities supporting clinical research as well as physicists and other staff supporting the conduct of biological experiments. It is expected that the inclusion of relevant physical data in high quality biological studies, will improve the intercomparison of preclinical studies. This will facilitate the accumulation of consistent data sets. Such datasets, when used for the development of biological effect models may in turn be used to improve our understanding of the relation of physical factors with preclinical and clinical outcomes. This report will focus on carbon ions (given that carbon is the only heavy ion currently used clinically); however, the suggestions offered may also be in part or in whole applicable to other ions including protons as well as helium and oxygen, which will be tested in clinical settings in the coming years. A brief introduction to the underlying issues and existing facilities is followed by suggested reference measures as well as more advanced physical measurements. Finally, recommendations for how such data should be incorporated into MC simulations are presented.
REVIEW OF THE TOPIC

2.A. Existing biological effect models
Particle therapy, particularly for heavy ions, is most distinct from x-ray therapy and therefore provides many unique challenges in terms of the elevated and variable RBE. Current approaches to manage the RBE in clinical practice are detailed below. While several models have been developed that describe RBE for clinical carbon ion radiation therapy, two distinct models are most commonly implemented.
In Japan, the method proposed by Kanai, combines in vitro cell survival data and empirical clinical data from their experience in fast neutron therapy, to calculate photonequivalent clinical dose. 13 The idea was that fast neutron therapy was the only high LET radiotherapy experience they could refer to at the time. The unique feature of Kanai's system is its two-step approach: obtaining biological RBE using in vitro cell survival data (LQ model) first and then rescaling biological RBE to clinical (final) RBE using the "known" fast neutron RBE. Their clinical results with carbon ion beams indicated that their approach fell within a sensible range: local control was observed with understandable rates of toxicities. Almost all of the Japanese clinical data are based on Kanai's system of calculating photon-equivalent doses. The more recent implementation of the modified MKM in Japan aimed to improve the robustness of biological RBE prediction/calculation for scanning beam configuration. While carbon ion beams are now introduced as a new option for reference radiation for biological RBE, and the dose-dependent RBE has also been made available, the method of rescaling to clinical RBE by fast neutron data remains the same in principle. [14] [15] [16] In Europe, a different biophysical model, the local effect model, or LEM was developed at the GSI Helmholtz Institute (Darmstadt, Germany) for their clinical application. Their treatment planning systems make RBE prediction exclusively by LEM, based on input data from photons without referring to other high LET clinical experience. 17 This approach claims the presumable advantage of being based directly on the more extensive photon clinical experience by combining photon LQ survival curves with "local dose distribution" on the nanometer (nm) scale using an amorphous ion track model. Over the years, LEM has gone through several stages of improvement, and additional DNA lesion of cluster type was introduced to modify the LQ model. 18 All clinical data and current practice in Europe are based on LEM to calculate RBE-weighted doses. 19 While the Japanese RBE system is based on in vitro data of HSG cell-line, the European LEMbased planning is performed using an a/b ratio of 2 Gy, representing the response of late responding normal tissues as well as chordoma, although the planning system can be adapted to any tumor and organ at risk, given its a/b ratio from x-ray therapy. In contrast to Japanese RBE models, the European LEM-based system does not further adjust the RBE based on available clinical data of other high LET radiation, such as fast neutron. In addition, it does calculate RBE at all arbitrary dose levels.
Employing different biophysical models clinically can result in different absorbed dose distributions even if the same RBE-weighted dose is prescribed and therefore the effectiveness of the same RBE-weighted dose will also differ. This complicates the analysis of clinical outcomes data. Additional in vitro as well as in vivo experiments are needed to (a) understand the biological damage and repair mechanisms (to improve the mechanistic characteristics of these models), (b) define input parameters for these models, and (c) generate data to test the predictive power of these models. Efforts have been undertaken to improve the quality of in vitro data for such endeavors. While the accuracy of biological studies has improved over the years and the importance of uniformity in laboratory conditions is increasingly apparent, it is now appreciated that particular attention should also be paid to the physical characteristics of the beam(s) used for experimental purposes.
2.B. Beam basics and existing facilities
The goal of radiation biology research efforts with heavy ion beams is to translate research laboratory findings to clinical practice. As such it is desirable that the basic research conducted is done with beams whose characteristics are as close as possible to beams used in clinical treatment. If access to clinical beams is limited, other beams, such as those at pure research facilities, are often used to conduct experiments. In such settings, it is often assumed by researchers that the relevant beam and experimental parameters will be extracted and understood, so that clinically relevant conclusions can be drawn. In other words, for radiation biology experiments, any heavy ion facility could be used if beams are properly characterized and understood. Currently, there are only 12 facilities worldwide offering heavy ion beam (mostly 12 C) of clinical quality and only a handful of additional nonclinical facilities offering a variety of ion beams. At present, there are five carbon ion clinical facilities in Japan, three in China and four in Europe, with additional facilities being under construction or in the advanced planning stage. (https://www.ptcog.ch/)
All existing clinical facilities are synchrotron-based, meaning the actual irradiation of tissue is pulsed, with pulses following the synchrotron cycle period. This can be relevant when dose rate effects are studied on relatively short time scales.
Eight out of these twelve clinical facilities employ an active scanning beam delivery method where the narrow monoenergetic pencil beam coming from the accelerator is magnetically steered in the lateral direction to "paint" a target layer with the therapeutic dose. The remainder of facilities scatter the narrow pencil beam to an initially large area which is subsequently collimated down to conform to the target shape to irradiate the whole volume simultaneously, using ridge filters and compensators to enlarge the monoenergetic Bragg peak into the clinical SOBP. The type of delivery technique is relevant because the number of ions, the set of ion species, and their energy spectra hitting each small unit of area per unit time are substantially different in the two techniques.
Each of the 12 clinical facilities is able to change the beam energy at the accelerator level. The rate of energy change usually determines the overall dose rate to volumetric targets. Typical values for physical dose rate are 1 Gy/L/min. Each of these facilities can also produce monoenergetic high-energy 12 C beams directly from the synchrotron with relatively low LET (~10 keV/lm), but all have problems in the efficient production of narrow monoenergetic low energy high LET beams (~100 keV/lm). Clinically, they overcome this challenge of irradiating superficial targets by introducing range shifters into the beam. Range shifters introduce neutron and other secondary particle contaminants. This is similar to when basic researchers may insert tissue equivalent material in order to position their biological specimen in the desired position along the beam path. In each situation, both clinicaland laboratory-based, this needs to be considered and characterized. The challenge is greatest for researchers studying biological effects at, near, or just distal to the Bragg peak. In order to increase the LET at the level of the samples, they must be placed with very high precision (sub millimeter precision) along the pristine Bragg peak. This is technically difficult and can introduce large uncertainties because of the uncertainty in the range of the particles, a problem that is exacerbated if a high precision positioning system is not available. Most studies are indeed performed using a small SOBP, even for cells in monolayers. In general, scanned beam facilities offer higher degrees of freedom to provide the user with specific LET or dose distributions.
Experiments using irradiation of samples with multiple ion species are possible only in a few facilities that have installed multiple ion sources, mostly 1 H and 12 C except for select centers planning or capable of 4 He and 16 O as well. The attractiveness of using clinical facilities for research stems from the fact they offer relatively high quality wellcharacterized clinical beams. However, this is offset by the limited availability of beam time for research. Several clinical institutions have separate, dedicated research (nonclinical) irradiation rooms. However, the beam characteristics may be different in such research-room beamlines, so extra care needs to be employed to characterize the research rooms appropriately.
Moreover, it is generally difficult -or impossible -to adapt the clinical facilities, even those with research beams, to targets of interest for pre-clinical research, especially in small animals. This is when the nonclinical research facilities may come into play. Nevertheless, clinical beams can serve a very wide spectrum of roles ranging from fundamental physics experiments, through radiation biology experiments, to testing electronics for space travel. Hence, these beams need to be well understood and characterized in order to produce high quality results for each experimental need.
The research rooms at Brookhaven National Laboratories (BNL), GSI Helmholtz Center for Heavy Ion Research, National Institute of Radiological Sciences (NIRS), MedAustron and Centro Nazionale di Adroterapia Oncologica facilities receive their beams from synchrotrons. At BNL, GSI, and NIRS, essentially all ions (lighter or heavier than C12) can be accelerated and prepared for radiation biology experiments. The synchrotrons are powerful enough to accelerate C12 ions to clinical therapeutic depths of 30 cm in water and above (e.g., BNL can reach to 1.5 GeV/u for Fe56 nuclei). However, synchrotrons cannot deliver beams below approximately 50 MeV/u without passive absorbers acting as range shifters whose effects on beam purity need to be quantified and accounted for. BNL and NIRS employ passive scattered beams while GSI has an active scanning beam for C12 ions in the room that used to be clinical before Heidelberg Ion Therapy (HIT) was brought online. All three facilities are setup to irradiate samples with monoenergetic ion beams as well as with an SOBP.
Worldwide about half a dozen cyclotron-based research laboratories offer heavy ion beams suitable for biological experiments. These laboratories can produce high LET beams with energies typically lower than approximately 50 MeV/u down to several MeV/u but with relatively high ion beam currents, for instance reaching to 10 13 12 C particles per second when the fastest clinical facilities reach to "only" 10 9 12 C particles per second. The field sizes are limited to approximately 10 cm in diameter or less and the dose homogeneity typically ranges between AE5% and AE10% across the irradiated field.
While addressing issues such as fragmentation may be challenging, researchers should not neglect more basic issues such as ensuring that the dose distribution and homogeneity at the samples across the irradiated field is known and acceptable to avoid uncertainties and ambiguities in what part of the sample got what dose and with which secondary ions. This is especially true for samples close to field edges.
In summary, numerous facilities offer ion beams for the conduct of preclinical studies. However, there are sizeable differences in the beam characteristics between facilities, particularly between pure research-based and newer clinical facilities. Differences between clinical quality beams to research quality include dose homogeneity, particle spectrum and LET spectrum hitting the samples, dose rate etc. Ion therapy facilities need to carefully characterize their beams, so that such differences can be recognized and reported, particularly as the number and characteristics of facilities continue to change in coming years. It is recommended that as research facilities add additional resources or beam sources, attention should be paid to maximize the similarities between new beams and those used clinically.
DOSIMETRY
3.A. Reference dose
If studies at different institutions are to be compared, the first and most obvious metric that must be assessed and reported is the absorbed dose delivered to the sample or tissue of interest. This first requires that the carbon ion beams are calibrated in terms of absorbed does to water according to the International Atomic Energy Agency (IAEA) TRS-398 code of practice. Compared to x-ray therapy, the main difference and limitation in reference carbon ion dosimetry is the absence of a primary dosimetric standard. Consequently, rather than being calibrated in a carbon beam, the response of ion chambers still refers to a cobalt-60 beam. Moreover, corresponding k Q values are analytically calculated and include a range of assumptions. Tabulated k Q values (e.g., in TRS-398 and DIN6801-1) do not tie back to a specific beam quality (e.g., a specific residual range) but are more general estimates of the response of the chamber. Correspondingly, the uncertainty in k Q in carbon ion dosimetry is much larger than is observed for x-ray therapy, being 2.8% for carbon ion beams as compared to 1.0% for high-energy x-ray beams. 20 Though these uncertainties are relatively small (compared to, e.g., uncertainties in RBE), an important conceptual objective of dosimetric standardization is to reduce all forms of uncertainty. Moreover, improving dosimetric precision also has practical importance as numerous biological studies use physical dose to assess biological impact; uncertainty in physical dose, thereby directly impacts the uncertainty in these biological metrics (e.g., RBE).
Establishing a primary standard for carbon dosimetry requires refinement of calorimetry measurements by the standards laboratories for carbon beams. While the technical aspects of calorimetry appear to be manageable, a major obstacle to establishing a calorimetry-based standard is simply that standards laboratories do not have routine access to carbon ion beams. 21 Hand in hand with calorimetry development is the need to establish a code of practice to define calibration elements such as reference conditions and beam quality specifications, allowing the calorimetry results to be broadly applicable. Having such a standardized code of practice would allow for the conceptually important aspect of making ion chamber-based clinical reference calibrations traceable to the National Institute of Standards and Technology or similar agencies.
Particularly until a primary standard is defined, including a corresponding code of practice, intercomparisons of clinical reference dosimetry are highly valuable. Ideally, a multi-center ion chamber intercomparison should be performed, where the primary ion chamber from all carbon ion facilities is brought together and placed sequentially in an identical carbon ion beam to determine the relative results. This was done with proton radiotherapy (personal communication, Paige Taylor), and while published results from the proton intercomparison are still pending, the approach provided an opportunity for direct intercomparison of chamber responses and k Q values. Unfortunately, such an intercomparison is relatively expensive and requires extensive coordination. A second type of intercomparison should be a beam output audit based on a remote mailable dosimetry system, such as the programs run by Imaging and Radiation Oncology Core (IROC) or the IAEA for x-ray and proton facilities. 22, 23 Participating facilities irradiate the mailed dosimeters to a known dose and under calibration/reference conditions, which are returned and read-out according to a standard read-out process. This intercomparison provides broad information on the consistency of clinical reference calibration between different institutions. Although mailable dosimeters do not provide the same precision as ion chambers, this program is in many ways easier to implement by virtue of it being a remote program.
3.B. Relative physical dose
Radiobiological studies will rarely be conducted under reference conditions, and it is essential to know the absorbed dose at different points in the radiation beam or in the specimen being irradiated. When treatment planning systems are used, this information will be collected as part of the commissioning process for the planning system. When there is no planning system, or to confirm the accuracy of the planning system, relative dosimetry of the absorbed dose is essential to quantify the dose or variations in dose across the specimen. Relative dosimetry of physical dose can be challenging because of complicated dosimeter responses.
3.B.1. Dosimeters
For relative dose measurements, ion chambers remain the gold standard for dosimetry, although a wide range of detectors can be used; basic considerations for point, planar, and volumetric detectors have been recently reviewed. 24 Nontrivial challenges exist for many common dosimeters, such as LET dependence, as LET may change substantially across the SOBP, as well as between the plateau, SOBP, and fragmentation tail. Many dosimeters have a particularly complicated response: rather than having a simple one-to-one LET-to-response dependence, the response of the dosimeter may also depend on the species depositing dose. For example, TLD respond differently to different ion species, even at the same LET. 25 Radiochromic film may also have this relationship. 26 While the detector response could be corrected based solely on knowledge of LET in a pure carbon ion beam, substantial fragmentation occurs even before the SOBP. 27 With protons, helium, and boron all contributing dose to variable degrees with depth in a carbon beam, the corresponding relationship between LET and dosimeter response may not be uniquely defined. 28 As a result of these challenges, dosimeters such as film are well suited for relative measurements orthogonal to the beam direction; ion chambers, because of their independence of LET, may be used at any position in the treatment field, including along the beam direction where LET is most variable.
3.B.2. Treatment parameters affecting relative dose
Numerous treatment parameters will affect the dose received by a given specimen in a particular experimental setup, although the particular set of parameters will depend on the facility and their mode(s) of operation. For example, relative dosimetry for pencil beam scanning systems will typically depend on relatively few parameters: uniformity across the treatment field and depth as a function of SOBP and range. Passively scattered systems will typically be characterized by factors describing field size (which may depend on specific snouts and/or scatterers), off-axis position, range, range shifter, SOBP, and depth. The impact of these parameters should all be established by the facility during commissioning of the beam, although this will most likely be done in general terms (e.g., output factors for regular rectangular field sizes and different snouts). Specific detailed measurements
The degree of dosimetric variability associated with changes in different treatment parameters should be known, and if the variability is greater than 2% across the range of values used in an experiment (e.g., uniformity across the treatment field), this difference should be accounted for. This may often be accomplished by use of a treatment planning system that has been well commissioned with extensive measurements, providing accurate physical dosimetry. A reasonable expectation for physical dose accuracy is that the planning system should match x-ray dosimetry standards; that is, be within 2% for static fields when examining the impact of a single parameter, and within 5% for any combination of parameters. 29 If such a planning system is not available, or the accuracy is inadequate (e.g., as has been seen with pencil beam algorithms in the thorax 30 ), management of this issue is likely to be based on measurements or more specific calculations (e.g., MC simulations of the experimental setup).
ADVANCED MEASUREMENTS
4.A. Overview
Carbon or other heavy ion beams need to be characterized not only in terms of physical dose, but also in terms of beam quality. Such measures include microdosimetric characterization as well as a knowledge of fragmentation products within the beam. Such measurements, while complex and time-consuming, contribute to our understanding of the relation of physical factors to biological effects. These measurements do not necessarily need to be performed for each individual biological experiment, however, a detailed characterization for the facility and beamline should be available and integrated into MC simulations as discussed later, and should be considered when designing any experiment.
Ideally, the LET distribution of the radiation field should be known in order to (a) assess the response of many dosimeters used in carbon ion therapy, and (b) explain the RBE of the radiation (or at least to provide a platform for comparison between different beams). Microdosimetric spectra of the radiation are typically measured with a proportional counter. More recently, silicon telescopes have also been developed and applied to carbon ion beams as well to measure the mass, charge, and kinetic energy of particles. 31, 32 By combining the results of a traditional proportional counter and a telescope system, it is possible to infer the LET spectra in addition to the fluence spectra of each fragment species. This would provide a comprehensive characterization of the carbon ion beam. 33 Additionally, fluorescent nuclear track detectors (FNTD) have been applied to measure the integral energy deposited by individual particle tracks, which can be used to investigate LET. 34, 35 Those detectors can even be coated with cell cultures. 36 However, one challenge with such assessments of LET is how to make LET assessments traceable to a national standard. As newer technologies to assess LET arise (MediPix 37 etc.), such issues may be mitigated by standardized measurements. However, as ultimately making LET measurements traceable to a national standard is a long-term prospect, in the mean-time, a common platform of comparison between institutions would be beneficial. A program such as the IROC proton therapy credentialing program (http://rpc. mdanderson.org/RPC/home_page/Proton_guidelines.htm), would be highly valuable for carbon ion therapy facilities, and should include uniform assessment of LET across carbon ion facilities. Standardization and consistency of LET assessment is of great importance in determining the biological effects as a function of the underlying physical factors, and may be essential to the development of mechanistic effect models.
Fragmentation of the primary beam is a relevant feature in carbon ion therapy. In a typical treatment plan, covering a target at 10-25 cm depth, only 50% of the incident ions Fig. 1) . Clinical facilities using passive scattering will significantly degrade the purity of the primary beam in front of the patient compared to scanning, where most of the fragmentation occurs in the patients' body. The actual spectral composition of the beam may be of some importance in determining its biological effectiveness. 38 The quality of the beam along a SOBP is generally characterized by its dose-average.
Linear energy transfer (LET d ), but direct biological comparison of SOBP and monoenergetic beams show that LET d does not completely reproduce the response. 4 The spectral difference can therefore account for biological variance. A further consideration (that may be different between research and clinical centers) is that the beam will have different composition depending on the material used in the beamline. The knowledge of these parameters is important to characterize the biological results and to perform accurate simulations. Spectral composition and its angular dependence have been measured in several centers, for example, Fig. 2 reports the data for C-ions at GSI.
Given the importance and complicated nature of the microdosimetric properties of a heavy ion beam, proper characterization of this is challenging but necessary. Methods and considerations for characterizing the quality of the ion beam are described below, along with other nonphysical dose considerations.
4.B. Beam divergence
Measuring the divergence at different locations can help in the selection of the optimal isocenter, especially if the facility lacks control over the beam's final focus and cannot correct the divergence.
Measurement technique
1. Place two objects of the same shape and size one outside of the exit window and one at the reference position. 2. Acquire a beam image with a film or digital beam imager. If the beam is perfectly parallel, no shadow or distortions are detected.
The methodology described above provides a direct indication of the beam divergence. 39, 40 However, this parameter strongly influences the particle spatial distribution throughout the irradiation field. Therefore, its quantitative characterization is included in the beam spatial distribution measurements. Controlling the beam divergence represents a useful tool to increase the beam size at the isocenter and improve the overall field homogeneity. For large radiation fields, a dose uniformity of <5% should be achieved, as it is required for large therapeutic particle fields with passive scattering method, unless it is accounted for in the experiment (e.g., through its incorporation into a planning system).
4.C. Time distribution
The characterization of the temporal structure within a particle bunch (also referred to as spill) is important for synchrotrons and should be provided to characterize the experiments at the facility.
Measurement technique
1. Acquire the beam profile over time with an ion chamber or with a plastic scintillator coupled with a timing device.
This can provide average and instantaneous dose rate, at least for nominal treatment conditions (e.g., specific field sizes). Additionally, this effort can be used to look for the presence of a nonuniform time distribution, manifesting as the presence of "spikes" in the spill profile, which might result in a dose cut-off distortion and thus affect the reliability of the dosimetry system. 41 
4.D. Purity and secondary particles
Purity relates to the fraction of accelerated particles at the target position. Incident beam purity is related to the production of secondary radiation from nuclear fragmentation of the primary ions along the beam line, in the exit window and in the air gap to reach isocenter. Backscattering from the room walls represents another source of fragments, especially for neutrons and photons. The contribution of secondary particles to the incident fluence is negligible in-beam but might become important out-offield. • at various locations up to 10 cm from the field edge with a 80 cc or 1000 cc EGG ion chamber (Far West Technologies, Goleta, CA, USA).
Microdosimetry:
• lineal energy spectra acquired with a tissue equivalent proportional counter (TEPC) at various locations up to 10 cm from the field edge. 43 3. Characterization of species and kinetic energy of all fragments:
• energy deposition spectra acquired in beam (0°-isocenter) and off-beam (for instance at 5°and 15°) with a pair of Silicon detectors.
44,45
• energy deposition and time-of-flight spectra acquired in beam (0°-isocenter) and off-beam (e.g., 5°and 15°) with a combination of plastic scintillation detectors and determination of absolute dose. [45] [46] [47] Desirable values: Incident beam purity, expressed in fluence, between 94% and 98% depending on the beam species and energy; lateral beam dose at 10 cm from field edge <1 mGy/delivered-Gy at the center of the field, independent of the beam species and energy. 42 Studying the yield and kinetic energy spectra of all fragments is more complex and time-consuming. Thus, a first characterization of the beam purity might include only dosimetry, microdosimetry, and energy deposition measurements at 0°. If the resulting values exceed the desirable values specified above, further measurements should be performed to study the contamination and possibly find countermeasures to minimize it.
As for neutron and gamma background, these measurements are even more lengthy and difficult than the characterization of secondary charged fragments. Provided the experiment is irradiating the sample with the primary beam, the dose in field due to secondary neutrons and gammas is very low compared with that of the primary ion beam. 48 In this setting, secondary particles can be neglected.
Studies of beam characterization have been performed in virtually all particle accelerator facilities with research programs in radiation biophysics. [41] [42] [43] [44] [45] [46] [48] [49] [50] [51] [52] [53] 
MONTE CARLO CALCULATIONS
5.A. The need for Monte Carlo
In order to analyze the results of a physics or biology experiment, it is not sufficient to have the beam experimentally characterized at a position or area outside of the experimental setup location. Detailed knowledge of the physical factors, dose, LET etc. at the point of interest (e.g., a cell culture plate) within the experimental preparation is necessary. This is depicted in Fig. 3 , position "C". The most detailed information is obtained using MC simulations of the experimental setup (Fig. 3, "Area 3") , which is feasible with standard MC codes. Ideally, the experimental geometry is modeled including the material composition of all elements in the beam path. This simulation has to be combined with initial beam information at a defined starting point of the MC simulations (Fig. 3,  plane "B") . The information at plane "B" has to be in parameterized form or, ideally, as a phase space. A phase space is a data file containing characteristics of a large number of particles. Phase spaces are typically defined at a specific plane perpendicular to the central axis of a beam.
Measurements are often done in water or water equivalent media (the latter typically refers to water equivalence for photon beam attenuation). It is thus important that the MC at least predicts the range in water correctly. Thus, before experiments are conducted, a simple depth dose curve should be measured to assess whether the delivered range equals the range predicted by the MC code. Typically, this may in fact not be the case as range-energy relationships may differ by a few mm based on different look-up tables (e.g., [54] [55] [56] [57] ). Furthermore, there are uncertainties in the mean excitation energies. If discrepancies are identified, the energy-range relationship can be re-normalized. Depending on the desired dosimetric accuracy, an estimate (either from MC or radiation protection measurements) about the background radiation should also be considered (e.g., neutrons emitted from the vault or backscattered radiation). 
5.B. Characterization of the beam using experiments
This is the typical scenario in which measurements are used to characterize the beam at plane "B" (Fig. 3) . These experiments, as described in the previous sections, have to be comprehensive enough to allow fitting all relevant parameters to match simulations of the radiation field with MC. They either have to allow generating a phase space file or a beam model with equivalent information content. In a phase space file, each individual particle should be listed and defined by its type, energy, direction, and flags providing some information about the history of the particle (e.g., whether the particle is either a secondary or a primary particle).
5.C. Characterization of the beam using existing simulation data
Alternatively, depending on the facility, a MC model of the in-room devices (Fig. 3 , "Area 2") might be made available. If the scientific experiments are being conducted at a facility with a commercially produced accelerator, such a MC model might contain confidential vendor information. In this case, a phase space parameterization at plane "B" based on the MC model might be useful and could be provided to the user community. Such a model is available for the HIT facility. 58 The model can be applied to create phase space files containing the characteristics (charge, mass, energy, coordinates and direction cosines and generation) of every particle (primary protons and carbon ions as well as secondary particles) at the end of the treatment head, for 255 initial beam energies. One phase space file corresponds to the scoring of the primary beam with the information about the energy, the position in the plane (X and Y positions), and the direction cosines (X and Y cosines). A second file contains the information about the secondary particles (except photons and electrons) in terms of energy, position, direction cosines, charge, and mass information of every particle. Also saved in both files is the generation number of the primary, which allows linking primary to secondary particles during the propagation process, which is important for statistical considerations. The use of phase space files is very useful to reduce the burden of modeling the treatment beam. For example, a large research facility, such as BNL, the structure of the beamline is generally very complex with numerous components requiring modeling (Fig. 4) .
5.D. Characterization of the beam using simulation data
If no simulation data are available and experiments are not feasible, the beam can be characterized performing new MC simulations. After being transported through a beam line connected to the particle accelerator (Fig. 3, "Area 1") , the beam enters the experimental room (Fig. 3, plane "A") . The beam at this plane is typically well described based on the beam optics. For instance, energy spread and angular spread are typically known within acceptable uncertainties from beam optics considerations. Note that the energy assumed by the accelerator control system may not translate into an expected beam range in water as the latter is affected by the material in the beamline and after the exit window.
Before reaching the user setup for experiments (Fig. 3 , "Area 3"), the beam may pass through fixed in-room devices, for example, a treatment head if experiments are being done at a treatment center (Fig. 3, "Area 2" ). This area may contain beam monitoring and beam shaping device. If detailed and validated geometrical information of this area in the room is available, then a model can be built within a MC code and subsequently, the beam entering the experimental setup can be described (Fig. 3, plane "B") . As an example, the actual Areas 2-3 at NASA Space Radiation Laboratory are shown in Fig. 4(b) .
It has been shown that proton and heavy ion delivery systems can be modeled quite accurately using MC. [58] [59] [60] Monte Carlo models of beam delivery systems (Fig. 3, "Area 2" ) need to be quite accurate when describing material in the beam path as high-Z material can alter the primary radiation field substantially. 60 Thus, the MC geometry simulation has to be validated before being used to generate a beam model or phase space.
5.E. Reporting results of Monte Carlo calculations
It is important to highlight that the results obtained with MC codes depend heavily on specific user settings. Typically, MC codes allow the choice of various interaction models, some based on fits to experimental data and others based on theoretical models (which are in turn based on experimental data) or a combination of both. The optimal setting most likely depends on the energy region of interest as well as the quantities of interest. For instance, modeling the emission angle of secondary particles from nuclear interaction may not be essential for an experiment that is sensitive to electromagnetic interactions only. In addition to the physics settings, results also depend on particle tracking parameters such as the step size or the production cut of secondary particles. For instance, Zahra et al. 61 have reported on the impact of user settings such as step sizes and production thresholds for carbon ion therapy simulations using Geant4. Consequently, in order to interpret results and accuracy of MC simulations and to compare with measurements at different institutions, these settings must be reported. Guidance can be found in the report of the AAPM Task group 268 entitled "Towards complete and accurate reporting of MC radiation transport studies". 62 As a minimum, the MC study should report on 1. Monte Carlo code including the release number and publication reference 2. Reference to previous validation of the code relevant for this particular application (if available) 3. Starting point of the MC simulation and initial radiation field (e.g., initial phase space) 4. Description of the modeled geometry (including a schematic drawing) 5. Hardcoded settings or default settings of the MC (e.g., step size limit) 6. Physics setting including underlying cross section data 7. User setting of the MC (e.g., step size, production threshold for secondary electrons and particles from nuclear interactions) 8. Statistical uncertainty of the results 9. Estimated modeling and/or systematic uncertainty, for example, based on the validation results 10. Discussion on the impact of uncertainties on the interpretation of the results
5.F. Uncertainties Monte Carlo calculations
Depending on the energy, particle and the user settings, the MC results are subject to intrinsic uncertainties in addition to statistical uncertainties. The attenuation of primary ion beams and integral yields of secondary particles is well described in water-like media; however, differences may occur for complex nuclear interactions and the resulting secondary particle field. Monte Carlo codes have been compared with experiments and also with each other. There has to be caution when interpreting publications comparing different codes as most researchers are familiar in detail with only one code and may thus not use the optimal recommended physics setting when comparing multiple codes.
Monte Carlo simulations have been validated in some therapeutic ion beams. However, these validations are often focusing on dose measurements only. [63] [64] [65] Dose comparisons are not sufficient to fully characterize the accuracy of a MC simulation, particularly for biological endpoints. Even for dose comparisons, there are uncertainties when considering different nuclear interactions. Often, the energy lost in nuclear interactions by primary particles is modeled correctly but the branching ratio into different reaction channels depends on the user physics setting and can, for instance, result in predicting higher yields of secondary particles of low energy as compared to lower yields with on average higher particle energies. The percentage of ions undergoing nuclear interactions is quite substantial. For a therapeutic carbon ion beam stopping in water, about 40% of the ions undergo a nuclear interaction. 49 Fragmentation spectra in carbon ion beams were measured to define the input in treatment planning systems. 66 One of the uncertainties is the mean excitation energy, or I value. These can typically adjusted in MC codes but several values have been reported in the literature. 56 A recent estimate of the uncertainty in I-values for water resulted in a value of 78.73 eV AE 2.89 eV when analyzing proton stopping powers. 67 This value is consistent with ICRU 90. 68 Note that as far as the range is concerned, if the MC range matches the range in measured water, the I value uncertainty reduces to the uncertainty relative to water.
While electromagnetic interactions causing ionization events are reasonably well understood, some nuclear interaction channels are not known precisely. For instance, doubledifferential cross sections are known with much lower accuracy compared to total charge-changing reaction cross sections for carbon ions. 69 Measurements reported for 95 MeV/ n ions 70 and for 400 MeV/n ions 71 demonstrate the expected accuracy for ions in high-Z material. In general, there are serious shortcomings in experimental data depending on ion type and energy relevant for therapy.
The experimental production of secondary particles has been compared with MC but we are far from a full validation of the physics in the region of interest for therapeutic ion beams. 47, 66, [72] [73] [74] Mainly, the FLUKA and Geant4 MC codes have been compared with experimental data not only for dose but also for secondary particle yields and cross sections. 69, 70, [75] [76] [77] Taleei et al. compared FLUKA, Geant4, and MCNPX to simulate 3 He ion beams in water and found in general very good agreement among these codes in terms of dose and secondary particle energy fluence. 78 The accuracy of certain MC settings and the chosen cross sections may also depend on user settings. 69, 77, 79 As an illustration, Fig. 5(a) shows some of the discrepancies in nuclear interaction cross sections between experimental data and two MC codes. Note the lack of experimental data for certain energy ranges. Similarly, Fig. 5(b) demonstrates the impact of different physics settings where, depending on the energy the match between experimental data and MC depends on the code and physics settings. Users of MC codes need to assess whether the code's validation is relevant for their specific application. It would be desirable to have a set of benchmarking experiments whose results could be used to standardize the validation of MC codes as has been proposed in proton therapy. 80 
5.G. Main Monte Carlo codes currently available for heavy ion research
There are several MC codes suitable for heavy ion simulations in the energy range of interest to radiation therapy applications. These include FLUKA, 82, 83 Geant4, 84, 85 MCNPX, 86, 87 SHIELD-HIT, 88 and PHITS. 89, 90 Other codes, specialized for heavy ion dose calculation have been developed as well. 91 For the most part, there is very little difference in the handling of particle tracking among the codes as they are all based on condensed history algorithms. The differences among codes are mainly in the underlying physics and secondary particle production.
All of these codes are multi-purpose MC codes that span a variety of applications. In addition to the "raw" codes, there are also frameworks that tailor these codes to radiation therapy applications such as GAMOS, 92 GATE, 93 PTsim, 94 TOPAS, 95 (all based on Geant4) and FICTION 96 based on FLUKA. The purpose of these "wrappers" is to extend the functionality of the basic codes and to provide user-friendly interfaces. For instance, TOPAS was particularly designed to model biology experiments for hadron therapy in order to allow nonexperts and nonphysicists to perform complex MC simulations without the need to engage in programming. 97 Monte Carlo extensions to these codes have been developed to model specifically the radiation effects on biological systems such as the DNA. Examples are the Geant4-DNA extension 98, 99 and the TOPAS-nBio framework, 100 both collaborative efforts based on Geant4. These may be helpful for analyzing results of biological experiments in more detail.
SUMMARY AND FUTURE DIRECTIONS
In order to maximize the clinical effectiveness of particle therapy, substantial obstacles must be overcome. Our understanding of the unique biological effects of high LET 81 particles, ranging from enhanced cell kill to increased immunogenicity, comes mainly from in vitro experiments. In order to allow quick translation into clinical practice, as our understanding of the biology of particle therapy increases we must ensure that the results can be correlated with the unique physical properties of particle beams. To accomplish this, researchers, physicists, biologists, engineers etc. should have a clear understanding of the potential differences that exist between particle beams including research-based versus clinical facilities. Uncertainty in the physical parameters unique to each beam and experimental setup should be minimized, recorded, and reported. While it is challenging to obtain initial advanced measurements (such as microdosimetric spectra) if such parameters can later be reliably reproduced in MC simulations, these values and uncertainties may be reported for subsequent experiments. Practically speaking, facility staff as well as physicists should be aware of the importance of reporting detailed physical parameters and their physical uncertainties. Moreover, biological researchers are encouraged to actively engage facility staff and physicists in the design and conduct of experiments and in the reporting of doses and dosimetric uncertainties.
One practical challenge for researchers is simply securing beam time with which to conduct experiments. Often beams in clinical use face substantial time pressure. Hence, researchers may depend primarily upon beams at pure research facilities. Nonclinical facilities should provide relatively pure beams (94-98% beam purity) of energies of clinical relevance (70-400 MeV/n) and for appropriate field sizes. Every effort should be made by research facilities to provide detailed data not only with regards to simple measures such as dose and uniformity but also for more advanced measures. In addition to reporting basic physical parameters, priority should particularly be directed toward identifying the presence of secondary particles and reporting microdosimetric parameters. Such detailed characterization data would ideally be published allowing experimentalists to refer to that work. Equally important, those conducting biological experiments should be aware of potential differences in beam characteristics, including the impact(s) that their unique experimental setups may introduce and report detailed data regarding uncertainties. As at clinical facilities, such detailed information and understanding almost certainly necessitates focused coordinated effort by the technical staff. This should include experimental design steps as well as dose and dosimetric uncertainty reporting. Researchers using clinical beams should not be exempt from such requirements. Here again, detailed dosimetric data should be determined for the experimental conditions, including microdosimetric data, MC input parameters, and other relevant details, and reported to the community as part of the publication information. As a community, researchers could also consider housing such data for clinical and research facilities in a central repository such as IROC. While it is understood that serious challenges exist for reporting data such as microdosimetric parameters (i.e., limited availability of TEPCs, issues with tracing values to a national standard etc.), these data are essential if the field is to improve the standardization of radiobiological studies and, in the long term, thereby advance clinical outcomes for patients treated with particle therapy. Moreover, there are continual technological advancements within the field, which may ultimately facilitate such measures. This includes the use of newer instruments such as Medipix, FNTD or even biological dosimetry.
In summary, we have identified a set of physical parameters and measurements that should be addressed by facilities supported by NCI to perform pre-clinical radiobiology of heavy ions. This information can, and should, be used when designing experiments at these facilities. We recommend the following:
1. Measured Bragg curve in water 2. Absolute dosimetry, including independent output check, as well as external ion chamber intercomparison until traceability to a primary standard can be established. 3. Relative dosimetry, including parameters of relevance to the beam being used (e.g., off-axis dose or beam uniformity, depth dependence, output factors, etc.)
using an ionization chamber. Variations in excess of 2% should be accounted for. 4 . Measured divergence at the isocenter 5. Measured time structure 6. Characterization of the beam quality at the isocenter by microdosimetry spectrum (TEPC), and full spectrum of fragments using a Si-telescope at 0°and at a small angle. 7. Providing all data on beamline characteristics for implementation in a MC simulation of the beam.
Based on the above set of beam evaluations, the following values should be reported in individual studies when presenting results from radiobiological experiments with heavy ions. These values will likely derive from measurements, MC simulations, and the facilities accelerator report:
1. Nominal ion species and maximum beam energy 2. Delivery modality (scanning vs scattered) 3. Bragg peak width 4. Physical dose to the tissue/location of interest (or range of doses if the dose varies by more than 2% across the specimen laterally or with depth) and medium of dose specification (water/medium) 5. Ion species distribution at the location of interest 6. LET distribution for each ion at the location of interest (most often from MC) 7. Dose rate of the radiation beam (instantaneous and average), including whether the beam is continuous or pulsed.
A detailed summary of recommended parameters, methods, reporting, and desired accuracy is presented in Table I . The desired accuracies reported represent a consensus of the convened panel.
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